News

Avantor Performance Materials appoints Michael Stubblefield as CEO.

GSK reports 5-year vaccine price freeze for countries graduating from GAVI Alliance.

FDA targets illegal online pharmacies that sell unapproved prescription drugs to US consumers.

GE Healthcare launches the Xuri IL-2 for the activation and expansion of T-lymphocytes.

Merck KGaA fill-finish expansion in Italy will be completed in 2017.

Cytovance Biologics and Selexys Pharmaceuticals enter an agreement for development of clinical trial materials.

PhRMA announces 119 new medicines are in development to treat mental and addictive disorders.

Brookfield continues to supply viscometers and rheometers for laboratory and on-line process control applications.

Pfizer will submit a NDA with FDA for palbociclib, a treatment for locally advanced or metastatic breast cancer.

SAFC offers commercial and pilot-scale continuous-flow capacity.

FDA approves Entyvio, an injection to treat adult patients with moderate to severe ulcerative colitis and Crohn's disease.

BMS and AbbVie receive FDA breakthrough therapy designation for elotuzumab, an investigational humanized monoclonal antibody for multiple myeloma.

Novartis settles its litigation with the US subsidiary of Sun Pharma regarding Gleevec.

Meissner moves into its new headquarters in Camarillo, California.

FDA issues complete response letter for Novartis' RLX030 for acute heart failure.

Ascend Laboratories and Masters Pharmaceuticals cited in seizure of $11 million in unapproved drugs.

Hospira has recalled one lot of labetalol hydrochloride injection, USP, due to visible particulates.

AstraZeneca rejects Pfizer's final offer of $118 billion for a proposed merger of the two companies.

SGS makes two senior appointments at its new GMP/GLP laboratory in Carson, California.

Advanced Scientifics and Chemic Laboratories enter a three-year joint cooperation agreement to collaborate on product development projects.

EMA opens registration for it's sixth annual workshop on pediatric drug research and development.

FDA and EMA release a draft joint proposal on the development of new drugs to treat Gaucher disease in children.

Boehringer Ingelheim announced that it is working on a program to make clinical trial data and other related documents more widely accessible for approved products and drug-development programs that have been terminated.

EMA and ECHA sign agreement to share information and work together on risk assessments.

Hillary Clinton will deliver a keynote address at the 2014 BIO International Convention in San Diego.

New manufacturing capacity at the Le Mans, France facility is being used to scale up antibody drug conjugates.

Santen will purchase Merck's ophthalmology products business in Japan and key markets in Europe and Asia Pacific.

AstraZeneca will collaborate with the Medical Research Council Laboratory of Molecular Biology to fund a range of pre-clinical research projects.

Draft guidance addresses the use of clinical pharmacology studies to determine biosimilarity of biologics.

FDA clarifies stability data recommendations for abbreviated new drug applications.